UCSF Memory and Aging Center Alzheimer's Disease Research Center UCSF About UCSF UCSF Medical Center UCSF Memory and Aging Center UCSF Memory and Aging Center Alzheimer's Disease Research Center Home Contact Us Make A Gift Sitemap
Clinic Education Research Caregivers Professional Training Events Resources Staff Art In Chinese En Espanol UCSF Memory and Aging Center

Research
Introduction
MAC Research
Autopsy Program
Healthy Volunteering
Investigator Requests


Observational Studies             Treatment Trials

Amyloid PET Imaging in AD, FTD and PPA

Study Director William Jagust, MD and Gil Rabinovici, MD
Sponsors National Institutes of Health and the Alzheimer’s Association
Recruiting? Yes
Official Study Title Amyloid PET in AD, FTLD & PPA: Diagnosis, Functional & Structural Correlations
Conditions Studied Behavioral variant frontotemporal dementia (bvFTD), semantic dementia (SD), progressive nonfluent aphasia (PNFA), Alzheimer's disease (AD), logopenic progressive aphasia (LPA), primary progressive aphasia (PPA), posterior cortical atrophy (PCA) and corticobasal degeneration (CBD)
Purpose The purpose of this study is to determine if amyloid PET imaging with Pittsburgh Compound-B (PIB) can improve diagnostic accuracy in discriminating between AD and FTD.
Eligibility  
Inclusion Criteria Participants must be over the age of 50 and meet criteria for either frontotemporal dementia (FTD), Alzheimer's disease (AD), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS) or healthy aging group. Patients are encouraged but not required to co-enroll in the Frontotemporal Dementia: Genes, Images and Emotions or New Approaches to Dementia Heterogeneity studies.
Exclusion Criteria Participants cannot have a history of another major neurological disorder that could be a potential cause of dementia, active substance abuse, major systemic illnesses including active cancer, renal or liver failure, respiratory failure requiring oxygen, or use of current medications likely to affect the central nervous system (CNS). Patients are not eligible if they have had a nuclear imaging study (PET or SPECT) in the past year or are actively enrolled in an anti-amyloid clinical trial.
What is Involved?  
Testing PET imaging at Lawrence Berkeley National Laboratory in Berkeley. Patients are studied with PIB (90 min scan) and FDG (30 min scan), with a break in between the two scans. The results of the scan will be released to the participant’s primary neurologist at the Memory and Aging Center, typically within 2-4 weeks.
Frequency of Visits One visit, some patients may be asked to come back for a second scan 1-2 years later.
Contact Information  
Coordinator Gil Rabinovici, MD
Phone (415) 514-2374
Materials Needed Prior to Evaluation None
Costs No costs will be charged for any of the study procedures. Patients will be sent a check for $100 if they complete both scans.

Back to Top

350 Parnassus Avenue, Suite 905 • San Francisco, California 94117 • (415) 476-6880
© 2009 The Regents of the University of California